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Abstract
Background: LXRs (Liver X Receptor α and β) are nuclear receptors that act as ligand-activated
transcription factors. LXR activation causes upregulation of genes involved in reverse cholesterol
transport (RCT), including ABCA1 and ABCG1 transporters, in macrophage and intestine. Anti-
atherosclerotic effects of synthetic LXR agonists in murine models suggest clinical utility for such
compounds.
Objective: Blood markers of LXR agonist exposure/activity were sought to support clinical
development of novel synthetic LXR modulators.
Methods:  Transcript levels of LXR target genes ABCA1 and ABCG1 were measured using
quantitative reverse transcriptase/polymerase chain reaction assays (qRT-PCR) in peripheral blood
from mice and rats (following a single oral dose) and monkeys (following 7 daily oral doses) of
synthetic LXR agonists. LXRα, LXRβ, ABCA1, and ABCG1 mRNA were measured by qRT-PCR in
human peripheral blood mononuclear cells (PBMC), monocytes, T- and B-cells treated ex vivo with
WAY-252623 (LXR-623), and protein levels in human PBMC were measured by Western blotting.
ABCA1/G1 transcript levels in whole-blood RNA were measured using analytically validated assays
in human subjects participating in a Phase 1 SAD (Single Ascending Dose) clinical study of LXR-623.
Results: A single oral dose of LXR agonists induced ABCA1 and ABCG1 transcription in rodent
peripheral blood in a dose- and time-dependent manner. Induction of gene expression in rat
peripheral blood correlated with spleen expression, suggesting LXR gene regulation in blood has
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the potential to function as a marker of tissue gene regulation. Transcriptional response to LXR
agonist was confirmed in primates, where peripheral blood ABCA1 and ABCG1 levels increased in
a dose-dependent manner following oral treatment with LXR-623. Human PBMC, monocytes, T-
and B cells all expressed both LXRα and LXRβ, and all cell types significantly increased ABCA1 and
ABCG1 expression upon ex vivo LXR-623 treatment. Peripheral blood from a representative
human subject receiving a single oral dose of LXR-623 showed significant time-dependent increases
in ABCA1 and ABCG1 transcription.
Conclusion:  Peripheral blood cells express LXRα and LXRβ, and respond to LXR agonist
treatment by time- and dose-dependently inducing LXR target genes. Transcript levels of LXR
target genes in peripheral blood are relevant and useful biological indicators for clinical
development of synthetic LXR modulators.
Background
The liver X receptors (LXRα and LXRβ, also known as
NR1H3 and NR1H2, respectively) belong to the nuclear
hormone receptor family of ligand-activated transcription
factors. LXRs are involved in controlling the expression of
a spectrum of genes that regulate cholesterol biosynthesis
and export in the liver as well as cholesterol efflux from
peripheral tissues [1-3]. In this way, LXRs act as choles-
terol sensors in the body. As such, the naturally occurring,
activating ligands for LXRs in vivo include specific oxidized
cholesterol metabolites such as 24 (S),25-epoxycholes-
terol, 22 (R)-, 24 (S)-, and 27-hydroxycholesterol [4].
When these ligands bind to LXRs, they displace co-repres-
sors and allow the ligand-bound LXR (which forms an
obligate heterodimer with retinoid X receptor (RXR), the
receptor for 9-cis-retinoic acid) to regulate the expression
of target genes by binding to specific promoter response
elements (LXREs) in target genes of LXR action [5-8]. In
the liver, LXRs regulate the expression of genes that con-
trol cholesterol metabolism and homeostasis, such as
cholesterol 7α-hydroxylase (in mice), which controls the
cholesterol/bile acid synthetic pathway, and sterol regula-
tory element-binding protein-1c, a key transcription fac-
tor that regulates expression of genes important in fatty
acid biosynthesis [9,10]. The role for each LXR isoform in
these processes has been elucidated by studies of pan-
LXRα/β agonists in LXRα KO mice [11,12]. LXRα and β
have also been shown to be expressed in macrophage,
where they play an important role in regulating choles-
terol efflux from macrophage in atherosclerotic lesions
[13-15]. In macrophage, LXR activation results in the
induction of several genes. Among these induced genes
are those encoding the ATP-binding cassette proteins,
such as ABCA1 and ABCG1, which are plasma membrane-
associated transport proteins that are responsible for
mediating cholesterol efflux as the initial step of the
"reverse cholesterol transport" (RCT) process thereby con-
trolling cholesterol mobilization from lipid-laden macro-
phages [16,17]. This "effluxed" cholesterol is
subsequently transferred to plasma acceptor proteins such
as high-density lipoprotein (HDL), which then delivers
excess cholesterol to the liver [17] for eventual excretion.
The action of LXR activation in the liver stimulates bile
acid production and excretion of this cholesterol. In addi-
tion, LXRs are expressed in the intestine where they limit
dietary cholesterol uptake by regulating the expression of
ABC family members ABCA1 and ABCG5/ABCG8 that
reside on the apical surface of enterocytes and act as efflux
pumps moving cholesterol out of absorptive cells into the
intestinal lumen [18].
Since LXRs are important regulators of reverse cholesterol
transport in macrophages, we and others have developed
synthetic LXR agonists that have been shown to be capa-
ble of stimulating macrophages in atherosclerotic plaques
to efflux the scavenged cholesterol and limiting plaque
progression [19-23]. This attribute is of particular disease
relevance because lipid accumulation in these cells,
through the uptake of oxLDL/LDL, is believed to be of
fundamental importance to the etiology and pathogenesis
of atherogenesis and atherosclerosis and other chronic
inflammatory diseases [24-28]. We have recently devel-
oped a novel LXR agonist LXR-623 that has been shown to
be anti-atherogenic in mouse models of atherosclerosis
(manuscript in preparation).
To assist in the clinical development of LXR-623, we
sought to identify peripheral blood biomarkers of LXR
agonist exposure and activity. Initial biomarker discovery
experiments in rodents revealed that peripheral blood
cells respond to orally dosed LXR-623 by substantially
increasing the transcriptional level of ABCA1 and ABCG1
in a dose-dependent manner. These data were confirmed
in primate studies, where it was shown that peripheral
blood cell expression of ABCA1 and ABCG1 mRNA was
significantly increased in a dose-dependent manner by
LXR-623 following 7 days of dosing. These findings were
extended to human cells by treating PBMC from normal
human donors ex vivo with LXR-623, which showed that
ABCA1 and ABCG1 expression was similarly regulated in
human peripheral blood cells. Furthermore, despite the
assumption that monocytes (the circulating macrophage-Journal of Translational Medicine 2008, 6:59 http://www.translational-medicine.com/content/6/1/59
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precursor cell type in PBMC) are the only LXR agonist-
responsive cell type in PBMC, it was shown that T- and B-
cells (in addition to monocytes) also express LXRα and
LXRβ and respond to LXR agonist treatment by upregulat-
ing ABCA1 and ABCG1 gene expression. Based upon these
findings, external standard based qRT-PCR assays were
developed to measure copy numbers of ABCA1 and
ABCG1 transcripts in whole blood cell RNA from human
subjects in a Phase 1 SAD (Single Ascending Dose) clinical
study of LXR-623. In a representative subject both ABCA1
and ABCG1 transcripts were rapidly upregulated with sim-
ilar temporal profiles following a single dose of LXR-623.
We conclude that the pharmacodynamic effects of syn-
thetic LXR agonist compounds can be measured in vivo by
monitoring the expression of selected LXR target genes in
peripheral blood cells. This approach should prove useful
for future clinical development of the present compound
and other candidate LXR agonist compounds.
Methods
Materials
All cell culture reagents were obtained from Gibco-Invit-
rogen (Carlsbad, CA). LXR agonists T0901317 [N-(2,2,2,-
trifluoro-ethyl)-N-[4-(2,2,2,-trifluoro-1-hydroxy-1-trif-
luoromethyl-ethyl)-phenyl]-benzenesulfonamide] [8,22]
and GW3965 [3-(3-(2-chloro-3-trifluoromethylbenzyl-
2,2 diphenylethylamino)propoxy)phenylacetic acid] [29]
were prepared following standard chemical syntheses
from published literature. LXR-623 was synthesized by
the Wyeth Chemical and Screening Sciences group. Mouse
Universal Reference Total RNA (catalog # 636657) and
Human Universal Reference Total RNA (catalog #
636538) was purchased from Clontech (Mountain View,
CA).
Mouse blood collection and RNA isolation
Blood (~300 uL) obtained from C57/Bl6 mice treated
with LXR-623 agonist compound was immediately mixed
with 1.3 mL of RNAlater (Ambion, Austin, TX), and fro-
zen at -80°C until further processing to RNA. RNA was
isolated from the thawed samples using the RiboPure
Blood Kit (Ambion #1928) following the manufacturer's
protocol. Quantitation of total RNA samples was per-
formed using an Eppendorf BioPhotometer 6131. RNA
quality was assessed using an Agilent BioAnalyzer with the
RNA Nano-chip (Agilent Technologies, Santa Clara, CA).
Rat blood and tissue collection and RNA isolation
Male Long Evans rats (Charles River Labs) weighing
approximately 300 g were administered a single gavage
treatment of 1 ml 2% Tween 80/0.5% methylcellulose
containing sufficient compound to deliver the indicated
doses. At various times following dosing, the rats were
anesthetized with isoflurane and peripheral blood was
removed by cannulation of the abdominal aorta. Approx-
imately 2.5 ml blood was collected into PAXgene Blood
RNA Tubes (Qiagen, Valencia, CA; # 262115) and RNA
was prepared according to the manufacturer's protocol.
Spleens were removed and frozen in liquid nitrogen prior
to processing for RNA isolation using the RNeasy Mini
RNA Isolation Kit (Qiagen). Total RNA was quantified by
RiboGreen (Invitrogen, Carlsbad, CA). For determination
of drug levels, compounds were extracted from EDTA
plasma into 1:1 acetonitrile:water and quantified by LC/
MS/MS.
Non-human primate blood collection and RNA isolation
Cynomolgus monkeys were treated for 7 days with LXR
agonist LXR-623 at either 15 mg/kg/day or 50 mg/kg/day
PO. Serum and whole blood samples were collected at
predose (day 0) and following dosing on day 7. Whole
blood (2.5 ml) was collected into PAXgene Blood RNA
Tubes (Qiagen catalog # 262115), incubated overnight at
room temperature, frozen on dry ice and stored at -80°C.
Isolation of RNA from PAXgene tubes was performed
according to the manufacturer's protocol. Quantitation of
total RNA samples was performed using an Eppendorf
BioPhotometer 6131 (Eppendorf, Hamburg, Germany).
RNA quality was assessed using an Agilent BioAnalyzer
with the RNA Nano-chip (Agilent).
Human PBMC and purified blood cell collection and RNA 
isolation
Whole blood was collected in 8 mL CPT tubes (Becton-
Dickinson, Franklin Lakes, NJ) from healthy donors and
the CPT tubes were processed for the isolation of PMBCs
according to the manufacturer's protocol. All PBMC preps
from a single donor were pooled for cell counts and sub-
sequent analysis. The cell number and cellular composi-
tion of each PBMC fraction was determined by Pentra
C60+ automated cell counter (Horiba ABX, Montpelier,
France). For ex vivo treatment with LXR agonist, the puri-
fied PBMC were resuspended in culture medium (RPMI +
10% fetal calf serum + 1% penicillin/streptomycin with
1% L-glutamine), transferred to 6-well (9.5 cm2 each) tis-
sue culture dishes at approximately 5 × 106 cells per well,
and 2 uM LXR-623 or vehicle (DMSO) were added. After
18 hours of culture, RNA isolation and qPCR analysis for
LXRα, LXRβ, ABCA1, ABCG1, and PLTP was performed.
At time of harvest, conditioned media was removed and
centrifuged at 450 × g for 5 minutes to pellet any cells that
were not adherent. The adherent cells remaining on the
plate were lysed by the addition of 1.2 ml RLT lysis buffer
(Qiagen) containing 150 mM 2-mercaptoethanol (Sigma,
St. Louis, MO) to the plate, the lysed cells were scraped
from the plate with a cell lifter, and the lysed cells in RLT
buffer were transferred to the cell pellet from the centri-
fuged conditioned media. The cell pellet was resuspended
by vortexing, and the total cell lysate was used for RNA
isolation using the RNeasy Mini RNA Isolation Kit (Qia-Journal of Translational Medicine 2008, 6:59 http://www.translational-medicine.com/content/6/1/59
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gen). Quantitation of total RNA samples was performed
using an Eppendorf BioPhotometer 6131; RNA yields
averaged 4.5 ug total RNA per culture well. RNA quality
was assessed using an Agilent BioAnalyzer with the RNA
Nano-chip (Agilent).
Fresh human PBMC, T cells, B cells, and monocytes from
normal human donors were purchased from AllCells
(Emeryville, CA). Each cell set was derived from the same
donor for comparison of response within a donor. The
cells were cultured, treated, and harvested as described
above for the PBMC cultures.
Human whole blood collection and RNA isolation
ABCA1 and ABCG1 expression was evaluated in human
clinical samples from a Wyeth-sponsored, single-center
Phase 1 single ascending dose (SAD) clinical study
(3201A1-100) of LXR-623 encompassing 40 healthy
human subjects. Whole blood was collected into PAXgene
tubes 2 hours prior to dosing and at time points of 2, 4,
12, 24, and 48 hours following oral administration of a
single dose of LXR-623. RNA was purified from the PAX-
gene tubes as described above for the non-human primate
samples. Sample RNA quality was assessed using an Agi-
lent BioAnalyzer with the RNA Nano-chip (Agilent), using
the RIN (RNA Integrity Number) algorithm [30] provided
with the instrument software. For these samples, the mean
RIN ranged from 4.1–8.8, with a mean RIN of 6.8.
Preparation and purification of cDNA
Purified RNA was converted to cDNA for subsequent qRT-
PCR using the High Capacity cDNA Archive Kit (Applied
Biosystems, Foster City, CA; PN4322171), following the
manufacturer's protocol. cDNA was subsequently purified
from the reaction mix using the QIAquick PCR Purifica-
tion kit (Qiagen PN28104) according to the instructions
provided with the kit.
Quantitative RT-PCR
All quantitative RT-PCR (qPCR, TaqMan®) reactions
described below were run on an Applied Biosystems 7500
Real Time PCR System using the following cycling param-
eters: Step 1: 50°C, 2 minutes; Step 2: 95°C, 10 minutes;
Step 3: 95°C, 15 seconds; Step 4: 60°C, 1 minute; repeat
Steps 3 and 4, 39 more times. Amplification of transcripts
for the genes of interest in each sample was compared to
the same assay run on a "standard curve" consisting of a
dilution series of cDNA prepared from RNA from an
appropriate tissue source, unless otherwise noted. Stand-
ard curve cDNA concentrations were determined empiri-
cally so that the CT values for the input experimental
samples fell within the experimental range of the respec-
tive standard curve for each transcript of interest. Input
cDNA amounts were determined by titration experiments
for each transcript. Amounts were chosen that best
allowed for changes in CT due to experimental conditions
while remaining on the standard curve. Data analysis was
performed according to the Relative Standard Curve
Method [31].
Quantitative RT-PCR on mouse RNA samples utilized the
following assays from Applied Biosystems: ABCA1,
Mm00442646_m1; ABCG1, Mm00437390_m1. The
mouse GAPDH transcript was measured for each sample
to normalize the amount of input RNA for each reaction,
using the Applied Biosystems Rodent GAPDH Control
Reagent Kit (# 4308313). Amplification of the genes in
each sample was compared to the same assay run on a
"standard curve" consisting of a dilution series of cDNA
prepared from RNA from a mixture of mouse tissues
(Mouse Universal RNA, Clontech # 636657).
Quantitative RT-PCR on rat RNA samples utilized the fol-
lowing oligonucleotide probe/primer sets: ABCA1, probe
FAM-AGGATGTGGTGGAGCAGGCG and primers, for-
ward 5'-GGGTGGCTTCGCCTACTTG-3' and reverse-5'-
GACGCCCGTTTTCTTCTCAG-3'; ABCG1, probe FAM-
TCACACATCGGGATCGGTCTC and primers, forward 5'-
GTACTGACACACCTGCGAATCAC-3' and reverse-5'-
TCGTTCCCAATCCCAAGGTA-3'. The rat GAPDH tran-
script was measured for each sample to normalize the
amount of input RNA for each reaction, using the Applied
Biosystems Rodent GAPDH Control Reagent Kit (#
4308313).
For measuring monkey transcripts, primate-specific
primer and probe sets for ABCA1 and ABCG1 were
designed with Primer Express Software (Applied Biosys-
tems, Foster City, CA). The ABCG1 probe, FAM-CTGGT-
GACGAGAGGCTTCCTCAGTCC and primers, forward 5'-
GGCAGAATTTAAAACTGCAACACA-3' and reverse-5'-
GGTGCCTGGTACTAAGGAGCAA-3', were designed using
Rhesus macaque nucleotide sequence (Genbank Acces-
sion # BV209042). Human ABCA1 TaqMan® reagents,
reported previously [32] were used for ABCA1 quantita-
tion following their validation using total RNA from
cynomolgus monkey liver (Biochain, Hayward, CA) and
results were normalized to human 18S rRNA (Applied
Biosystems Eukaryotic 18S rRNA Control Assay
Hs99999901_s1) following validation of this 18S rRNA
assay on monkey RNA.
For measuring human transcripts, the following quantita-
tive RT-PCR assays were obtained from Applied Biosys-
tems: ABCA1, Hs00194045_m1; ABCG1,
Hs00245154_m1; PLTP, Hs00272126_m1. The human
GAPDH transcript was measured for each sample to nor-
malize the amount of input RNA for each reaction, using
the Human GAPDH Control Reagent Kit (# 402869).
Amplification of the genes in each sample was comparedJournal of Translational Medicine 2008, 6:59 http://www.translational-medicine.com/content/6/1/59
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to the same assay run on a "standard curve" consisting of
a dilution series of cDNA prepared from RNA from a mix-
ture of human tissues (Human Universal RNA, Clontech
# 636538).
Measurement of ABCA1 and ABCG1 transcripts in blood
samples from the human clinical study of LXR-623 in
healthy human subjects was performed using the same
Applied Biosystems human TaqMan assays as described
above (ABCA1, Hs00194045_m1; ABCG1,
Hs00245154_m1; GAPDH, Endogenous Control Kit #
402869). However, an ''external standard'' approach was
utilized, in which TaqMan data from each assay is com-
pared to a standard curve generated with known quanti-
ties of pre-prepared transcript for each target. ABCA1,
ABCG1 and GAPDH cDNAs in pXL5 cloning vectors were
obtained from Origene (Rockville, MD). Pure synthetic
standards for each transcript were prepared by in vitro
transcription and purified. Transcripts were quantitated,
diluted to 109 copies/mL, aliquoted and stored at -80°C
until use. Data generated from samples were compared to
standard curves utilizing these synthetic standards, quan-
titated and normalized in terms of number of target tran-
scripts per 106 GAPDH molecules.
For human TaqMan assays, two-step RT-PCR reactions
were performed using the TaqMan Gold RT-PCR Kit from
Applied Biosystems (cat # N808-0233) according to the
manufacturer's instructions. The kit includes TaqMan PCR
Core Reagents (catalog # N808-0228), TaqMan Reverse
Transcription Reagents (catalog # N808-0234) and Taq-
Man GAPDH Control Reagents (catalog # 402869). qPCR
reactions were run on an Applied Biosystems 7500 Real
Time PCR System using the following cycling parameters:
Step 1: 50°C, 2 minutes; Step 2: 95°C, 10 minutes; Step
3: 95°C, 15 seconds; Step 4: 60°C, 1 minute; repeat Steps
3 and 4, 39 more times. Data analysis was performed
according to the Relative Standard Curve Method [31].
Microarray analysis of global gene expression
PBMC were purified from normal human donors (n = 4),
and separately treated ex vivo as described above with
either 2 uM LXR-623 or vehicle (0.1% DMSO) for 18
hours. RNA was purified as described above, and ampli-
fied and labeled using the Ovation Biotin Labeling and
RNA Amplification System (NuGEN, San Carlos, CA). The
labeled RNA was then used for microarray analysis using
the GeneChip® HG U133 2.0 Plus array (Affymetrix, Santa
Clara, CA). Expression profiling was performed on the
GeneChips® as described previously [33]. Hybridization
signal intensities of probe sets representing each gene
were measured for individual samples in each cohort
group (LXR-623 treated vs. vehicle), and an average signal
intensity for that gene was then calculated and compared
to the average signal values from the other cohort. Genes
were judged to be changed significantly by treatment if the
change in the mean hybridization signal intensity for the
probe set(s) representing that gene were > 2 fold higher or
lower in the treatment group than in the control group,
with a p-value < 0.05 as determined by Student's t test.
Analysis of protein expression by immunoblotting
PBMC was isolated from human blood collected in 8 ml
CPT-citrate tubes (within an hour of collection), and
plated onto 100 mm tissue culture dishes in RPMI con-
taining 10% FBS, 2 uM L-glutamine and 50 IU/ml penicil-
lin and 50 ug/ml streptomycin at a density of 10 million
cells/plate. After allowing cells to settle for 90 minutes, the
cells were treated with or without LXR agonists (2 uM) for
24 hours or 48 hours. Cells were lysed at the end of the
incubation in 1 × Cell lysis buffer (Cell Signaling Technol-
ogies) containing Pefabloc SC (protease inhibitor) on ice
for 10 minutes (500 ul/plate). Both adherent and non-
adherent cells were collected. Equal volumes (16.25 ul) of
cell lysate were loaded into each well of NuPAGE 4–12%
Bis-Tris gels (Invitrogen), and Full-Range molecular
weight markers (RPN800, GE Healthcare) were used to
assess molecular weights. Separated proteins were elec-
troblotted onto a nitrocellulose membrane (Invitrogen).
The membranes were blocked in 5% Blot-QuickBlocker
(Gbiosciences, St. Louis, MO) for one hour followed by
washing in washing buffer (PBS, 0.1% Tween20). To
determine the equivalence of protein loading between
samples, actin protein in each sample was detected by
Western blotting using an anti-actin antibody (Actin
(1–19)-HRP, Santa Cruz, 1:2000). In addition, protein
loading was assessed by staining the membrane with Pon-
ceau S (Sigma). Duplicate membranes were blotted sepa-
rately with anti-ABCA1 (Novus Biologicals, NB400-
10555, 1:500), anti-ABCG1 (Abcam AB36969, 1:2500),
or anti-LXRα (Novus NB300-612, 1:400). Unbound anti-
bodies were removed by washing the membrane three
times for 15 minutes each in washing buffer and were
then incubated with secondary antibodies (anti-goat-
HRP, Chemicon or anti-rabbit-HRP, NEF812001 Perkin
Elmer 1:2000) for one hour followed by another three
washes in the washing buffers as above. Proteins of inter-
est were detected by chemiluminescence using ECL West-
ern blotting detection reagents (Amersham). Correct
bands were identified by molecular weight, and specificity
was confirmed by comparing with a duplicate blot incu-
bated with a different antibody.
Results
LXRs are expressed in peripheral blood mononuclear cells
Expression of LXRα and β in tissue macrophage and dif-
ferentiated THP-1 cells has been well established
[8,15,34-36], but scant evidence exists for expression of
LXRs in circulating peripheral blood cells. Therefore,
quantitative RT-PCR (TaqMan®) was performed on RNAJournal of Translational Medicine 2008, 6:59 http://www.translational-medicine.com/content/6/1/59
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isolated from PBMC from normal human donors, using
assays designed to measure human LXRα or LXRβ tran-
scripts. LXRα and LXRβ were both found to be expressed
in PBMC (Fig. 1A). The presence of LXRα protein was con-
firmed by Western blotting of cell lysates from purified
human PBMC from two separate donors with an anti-
LXRα polyclonal antibody (Fig. 1B). Western analysis
with LXRβ antisera in these same lysates was attempted
but failed to detect a specific band of the proper size, pos-
sibly due to technical difficulties related to the available
anti-LXRβ antibodies that were used (data not shown).
LXR agonists induce gene expression in rodent peripheral 
blood cells in vivo
To determine whether the presence of LXRα and LXRβ in
peripheral blood cells would result in regulation of gene
expression, a single oral dose of LXR-623 was adminis-
tered to normal C57/Bl6 mice. Four hours post-dosing,
the transcript levels of LXR target genes ABCA1 and
ABCG1 in peripheral blood RNA were significantly
increased compared to vehicle-treated mice (Figure 2A). A
more comprehensive study was performed in rats, in
which three structurally diverse LXR agonists, T0901317,
GW3965, and LXR-623 were administered to normal
male rats. Three hours following treatment, the expression
levels of LXR target genes ABCA1 and ABCG1 were
strongly induced in RNA from whole blood of all animals
treated with the LXR agonists (Figure 2B). In both rodent
species, the magnitude of ABCA1 induction was signifi-
cantly greater than the magnitude of ABCG1 induction. In
rats, the induction of ABCA1 and ABCG1 expression in
peripheral blood cells was temporally correlated with
plasma drug levels, with plasma concentrations of LXR-
623 and ABCA1 and ABCG1 expression peaking three
hours after a single dose (Figure 2C) and then diminish-
ing as plasma drug levels decreased with clearance.
Finally, to determine whether the in vivo elevation of
ABCA1 and ABCG1 mRNAs reflected the potency of ago-
nists to activate LXR receptors, rats were treated with a
range of doses of GW3965 (Figure 2D) or LXR-623 (Figure
2E). Since the potency of these ligands for activation of rat
LXRα or LXRβ is not known, the potency for activation of
ABCA1 expression in mouse J774 macrophages (data not
shown) was used as an approximation. For GW3965, sig-
nificant induction of ABCA1 or ABCG1 in peripheral
blood cells did not occur until plasma concentrations
moderately exceeded the 0.23 uM EC50 for ABCA1 induc-
tion in J774 cells. Similarly, induction of ABCA1 and
ABCG1 in peripheral blood cells by LXR-623 also required
plasma concentrations in excess of the 0.42 uM EC50 for
ABCA1 induction in J774 cells. Together, the dose
dependence, temporal correlation, and activity of three
structurally diverse ligands indicate that in vivo peripheral
blood ABCA1 and ABCG1 gene expression is directly reg-
ulated by LXR.
Although gene induction in peripheral blood was corre-
lated with plasma drug levels, the critical physiological
effects of LXR activation are thought to reside within tis-
sues such as the intestine, liver, or macrophages within the
atherosclerotic lesion. Gene expression or drug concentra-
tion within these tissues cannot be easily monitored. To
determine whether activation of gene expression in
peripheral blood cells could provide insight into gene reg-
ulation within tissues, the induction of ABCA1 and
ABCG1 within the spleen, an organ highly enriched in
immune system cells, was compared to induction in
peripheral blood cells. For GW3965, there was a strong
correlation between the induction of ABCA1 or ABCG1 in
the blood and spleen (Figure 2D). However, for LXR-623
the spleen appeared to have increased sensitivity relative
to the peripheral blood at low plasma concentrations
LXRs are expressed in peripheral blood cells Figure 1
LXRs are expressed in peripheral blood cells. (A) RNA 
from peripheral blood mononuclear cells obtained from nor-
mal human donors was assayed for LXRα and LXRβ tran-
script levels using qPCR. Expression values were normalized 
to GAPDH levels, represented as the mean +/- SEM. (B) 
LXRα protein levels in protein extracts from PBMCs from 
these same donors were detected by Western blotting using 
rabbit anti-human LXRα polyclonal antisera.
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LXR agonists increase ABCA1 and ABCG1 mRNA levels in rat peripheral blood cells Figure 2
LXR agonists increase ABCA1 and ABCG1 mRNA levels in rat peripheral blood cells. (A) Normal C57/Bl6 mice 
on normal chow were orally dosed with a single administration of 50 mg/kg LXR-623 (623) or vehicle (VEH). At 4 hours post-
dosing, peripheral blood expression of ABCA1 and ABCG1 mRNA was quantified by real-time PCR, using GAPDH as the nor-
malizer. The bars indicate the normalized mean transcript levels +/- SEM (n = 4 per group). (B) Male Long Evans rats were 
administered a single dose of 10 mg/kg T0901317 (T0), 30 mg/kg GW3965 (GW), 30 mg/kg LXR-623 (623) or vehicle (VEH) by 
oral gavage. Three hours later peripheral blood expression of ABCA1 and ABCG1 mRNA was quantified by real-time PCR 
(100 ng RNA/assay). All expression values were normalized for GAPDH mRNA, with the level of expression in rats treated 
with vehicle defined as 1.0. Values are the mean +/- SEM (n = 6 per group). (C) Male Long Evans rats were administered a sin-
gle dose of vehicle (open circles) or 30 mg/kg LXR-623 (filled circles) by oral gavage. At the indicated time points plasma con-
centration of LXR-623 (uM) and peripheral blood cell expression of ABCA1 and ABCG1 were determined. Values are the 
mean +/- SEM (n = 6 per group). (D) Male Long Evans rats were administered a range (0.01 to 30 mg/kg) of GW3965 by oral 
gavage. Three hours later plasma GW3965 concentration, peripheral blood ABCA1 and ABCG1 expression, and spleen 
ABCA1 and ABCG1 expression were quantified. The induction of gene expression in the peripheral blood (open circles) and 
spleen (filled circles) is plotted as a function of the plasma drug concentration. The EC50 for GW3965 induction of ABCA1 
expression in murine J774 macrophages is denoted for reference. Values are the mean +/- SEM (n = 6 per group). (E) As above, 
except that rats were treated with a range (1 to 30 mg/kg) of LXR-623. * p < 0.01 compared to vehicle treatment, as deter-
mined by Student's t test.
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(Figure 2E). Whether this difference between ligands
reflects differing levels of LXRα and LXRβ expression in
blood cells versus spleen, or is due to some other factor
such as differing coactivator abundance, remains to be
determined. These initial results indicate that induction of
LXR target gene regulation in the peripheral blood may
serve as an indicator of target gene induction in relevant
tissues.
ABCA1 and ABCG1 transcription in peripheral blood cells 
of non-human primates is regulated in a dose-dependent 
manner by oral dosing of LXR-623
A study was performed in non-human primates to deter-
mine whether peripheral blood cells in higher species are
responsive to LXR agonist treatment, and to evaluate the
effect of prolonged LXR agonist dosing on peripheral
blood expression of ABCA1 and ABCG1. Twelve
cynomolgous monkeys maintained on normal chow were
orally dosed with 0, 15 and 50 mg/kg/day of LXR-623 (n
= 4 per dose group). Blood was collected prior to the first
dose (day 0) to serve as a baseline and again on day 7.
RNA prepared from whole blood was used for gene
expression analysis of ABCA1 and ABCG1 by qPCR. In
contrast to rodents, ABCG1 changed with much greater
magnitude in primate blood cells than ABCA1 in response
to LXR-623 at all doses tested (Figure 3). At day 7, ABCA1
expression (Figure 3A) was significantly increased by 15
mg/kg/day LXR-623 (2.1 fold vs. vehicle, p = 0.0135) and
50 mg/kg/day LXR-623 (3.4 fold vs. vehicle, p = 0.0006).
The data suggested a dose-dependent increase in ABCA1
expression between the 15 mg/kg/day and 50 mg/kg/day
doses at day 7, but the difference between doses did not
reach significance (p = 0.12). Peripheral blood induction
of ABCG1 by LXR-623 treatment at day 7 was much
greater than was seen for ABCA1; the 15 mg/kg/day dose
group showed levels of ABCG1 significantly increased by
9.8 fold vs. vehicle (p < 0.001) and dosing at 50 mg/kg/
day increased ABCG1 levels by 29.8 fold vs. vehicle (p <
0.001). The difference between doses was also significant
(p < 0.001).
Human peripheral blood mononuclear cells respond to ex 
vivo LXR-623 exposure by increasing expression of LXR 
target genes
To determine whether the transcriptional effects of LXR
agonists on peripheral blood cells that were seen in mouse
and monkey could be translated to humans, PBMC were
purified from normal human donors and treated in cul-
ture with either vehicle (0.1% DMSO), 0.05 uM or 2 uM
LXR-623 for 18 hours. RNA purified from these PBMC cul-
tures was profiled using Affymetrix HG U133 Plus 2.0
arrays to evaluate the genes that are regulated in periph-
eral blood cells by LXR-623. Table 1 shows a list of genes
associated with reverse cholesterol transport and lipopro-
tein metabolism that were significantly changed in
human PBMC by treatment with LXR-623. ABCA1 and
ABCG1 were two of the top genes that changed with the
greatest magnitude and significance. Other genes that
have been previously shown to be regulated by LXR in var-
ious target tissues were found to be regulated in human
PBMC by LXR-623, including steroyl-CoA desaturase [37],
apolipoproteins C1 and C2 [38], phospholipid transfer
protein [39], low density lipoprotein receptor [40], apoli-
poprotein E [38], and LXRα itself (NR1H3) [41].
The regulation of these target genes by LXR-623 in human
PBMC was confirmed by a second set of experiments
LXR-623 upregulates transcription of ABCA1 and ABCG1 in  monkey whole blood cells proportional to dose Figure 3
LXR-623 upregulates transcription of ABCA1 and 
ABCG1 in monkey whole blood cells proportional to 
dose. Cynomolgous monkeys maintained on normal chow 
were orally dosed with 0, 15 and 50 mpk/day of LXR-623 for 
7 days (n = 4 per dose group). Blood was collected on day 7 
of dosing, and RNA was prepared from whole blood for gene 
expression analysis of ABCA1 and ABCG1. qPCR was per-
formed using assays designed to measure monkey (A) 
ABCA1 and (B) ABCG1 transcripts, and the measured 
amounts of these transcripts were normalized to monkey 
18S RNA levels in each sample. Bars indicate the mean fold 
change of normalized ABCA1 or ABCG1 transcript levels +/- 
SEM in the indicated dose group compared to vehicle treated 
animals at the same time point. *p < 0.05, **p < 0.01 com-
pared to vehicle treatment, as determined by Student's t test.
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using blood from different human donors. qRT-PCR
assays designed to measure human ABCA1, ABCG1, and
PLTP were performed on RNA obtained from purified
human PBMC treated in culture with LXR-623 as
described above for the gene chip experiments. These
experiments confirmed that mRNA for ABCA1, ABCG1,
and PLTP was significantly upregulated in human PBMC
by LXR-623 (Figure 4). In addition, this transcriptional
induction was found to result in increased levels of
ABCA1 and ABCG1 protein in the PBMC cell lysates as
determined by Western blotting (Figure 5).
LXR-623 treatment of human PBMC in vitro significantly increases transcription of ABCA1 and ABCG1 Figure 4
LXR-623 treatment of human PBMC in vitro significantly increases transcription of ABCA1 and ABCG1. Periph-
eral blood mononuclear cells (PBMC) were purified from normal human donors (n = 3), transferred to cell culture dishes, and 
treated with vehicle (0.1% DMSO) or LXR-623 at either 0.05 uM or 2 uM for 16 hours. Following culture, cells were harvested 
and RNA was isolated for gene expression measurements of human ABCA1, ABCG1, PLTP, and GAPDH (normalizer gene) 
using qPCR. Bars indicate the average normalized transcript level across the three donors for each dose, +/- SEM. *p < 0.05, 
**p < 0.01 compared to vehicle treatment, as determined by Student's t test.
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Table 1:  Up-Regulated Human Peripheral Blood Biomarkers of LXR-623 Activity
Gene Symbol Gene Title Fold Change p-Value
ABCG1 ATP-binding cassette, sub-family G (WHITE), member 1 43.83 7.9E-08
SCD stearoyl-CoA desaturase (delta-9-desaturase) 24.59 1.4E-07
ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1 19.54 7.0E-08
APOC1 apolipoprotein C-I 13.37 2.5E-07
SREBF1 sterol regulatory element binding transcription factor 1 6.60 2.7E-03
PLTP phospholipid transfer protein 5.81 9.0E-05
APOC2 apolipoprotein C-II 4.17 4.2E-06
LDLR low density lipoprotein receptor (familial hypercholesterolemia) 3.91 2.4E-04
NR1H3 nuclear receptor subfamily 1, group H, member 3 3.85 1.0E-03
FADS1 fatty acid desaturase 1 3.01 3.9E-05
APOE apolipoprotein E 2.85 1.6E-02
Selected genes changed significantly in human PBMC following ex vivo treatment with LXR-623. Peripheral blood mononuclear cells were purified 
from normal human donors (n = 4) and treated in culture with either vehicle (0.1% DMSO) or 2 uM LXR-623 for 18 hours. RNA purified from 
these PBMC cultures was profiled using Affymetrix HG U133 Plus 2.0 arrays to evaluate the genes that are regulated in peripheral blood cells by 
LXR-623. Shown is a list of genes associated with reverse cholesterol transport and lipoprotein metabolism that were significantly changed in 
human PBMC by treatment with LXR-623, along with fold-change and statistical significance.Journal of Translational Medicine 2008, 6:59 http://www.translational-medicine.com/content/6/1/59
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Multiple cell types in human PBMC express functional 
LXRα and LXRβ
Since it is well documented that macrophages express
LXRs and respond to LXR agonists by increasing expres-
sion of certain LXR target genes [14,15,35], it was pre-
sumed that the LXR-responsive cell type in PBMC would
most likely be monocytes, the precursor cell type to mac-
rophages. To test this hypothesis, PBMC and the compo-
nent cell-types of PBMC (moncytes, T cells, and B cells)
were purified separately from blood obtained from nor-
mal human donors. These cell types were cultured sepa-
rately with 2 uM LXR-623 (or vehicle) for 18 hours,
followed by RNA isolation and qPCR analysis for LXRα,
LXRβ, ABCA1, and ABCG1. Without LXR-623 treatment,
LXRα was found to be most highly expressed in mono-
cytes, but expression of LXRα was also seen in T cells and
B cells (Figure 6A). In contrast, basal expression levels of
LXRβ were more similar in all cell types in PBMC (Figure
6B). Upon treatment with LXR-623, expression of LXRα
mRNA was significantly increased in PBMC and mono-
cytes, but not in T cells and B cells (Figure 6C), while LXRβ
expression remained constant in all cell types regardless of
LXR agonist treatment (Figure 6D). Interestingly, ABCA1
and ABCG1 differed in their regulation in different blood
cell types following LXR agonist treatment. Monocytes
were shown to express relatively high basal levels of
ABCA1, and treatment with LXR-623 resulted in approxi-
mately 6 fold induction of ABCA1 mRNA levels (Figure
6E). T cells and B cells expressed very low, but measurable
levels of ABCA1 mRNA, which was induced > 200 fold in
T cells and > 20 fold in B cells, but the overall ABCA1
expression level in these cell types was still extremely low
compared to PBMC and monocytes (Figure 6F). In con-
trast, ABCG1 was expressed and significantly regulated by
LXR-623 in all PBMC cell types (Figure 6G).
ABCA1 and ABCG1 expression is increased in peripheral 
blood of human subjects following oral administration of 
LXR-623
In order to accurately and precisely measure ABCA1 and
ABCG1 transcript levels in RNA from peripheral blood
samples of human subjects prior to and following a single
oral dose of LXR-623, external standard qRT-PCR assays
for the two target genes and a normalizer transcript
(GAPDH) were developed and analytically validated.
Dilutions of in vitro ABCA1 and ABCG1 transcripts con-
taining from 10 to 100,000,000 copies of ABCA1 and
ABCG1 RNA were reverse transcribed into cDNA and PCR
LXR-623 treatment of human PBMC ex vivo significantly increases protein levels of ABCA1 and ABCG1 Figure 5
LXR-623 treatment of human PBMC ex vivo significantly increases protein levels of ABCA1 and ABCG1. 
Peripheral blood mononuclear cells (PBMC) were purified from normal human donors (n = 3), transferred to cell culture 
dishes, and treated with vehicle (0.1% DMSO) or LXR-623 (2 uM) for either 24 or 48 hours. Following incubation, cells were 
lysed and protein extracts were separated on SDS-PAGE and blotted with antisera raised to ABCA1, ABCG1, or actin (to 
serve as an indicator of protein loading per lane). Horseradish peroxidase-linked secondary antibodies were bound to the 
immobilized protein/antibody complexes, and proteins were visualized by chemiluminescence. Duplicate lanes for each treat-
ment reflect the two different donors analyzed in this experiment. Molecular masses were estimated by the relative mobility of 
protein markers run in an adjacent lane on each gel.
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amplified on an ABI 7900 realtime PCR system (Figure 7,
panels A and B). The interday efficiency for PCR amplifi-
cation was 90.4% for ABCA1 (range: 84–100%) and
95.4% for ABCG1 (range: 90–104%). The calibration
curves (n = 5 replicates at each level run on 5 separate
days) for the ABCA1 and ABCG1 transcripts showed
acceptable precision and accuracy (< 30% CV and 30%
bias) from 1,000 to 100,000,000 copies. A similar exter-
nal standard method was developed and analytically vali-
dated for the measurement of GAPDH RNA (data not
shown). Normalized levels of ABCA1 mRNA ranged from
19,700 – 99,400 copies ABCA1/10^6 copies GAPDH in
eleven healthy (untreated) subjects (6 males and 5
females, age 26-61 yrs), and levels of ABCG1 mRNA
All cell types in human PBMC express functional LXRα and LXRβ Figure 6
All cell types in human PBMC express functional LXRα and LXRβ. Peripheral blood mononuclear cells, monocytes, 
T-cells, and B-cells were purified from normal human donors (n = 3). After acclimation for 1 hour in culture, replicate cultures 
for each cell type from each donor were treated with either vehicle (0.1% DMSO) or LXR-623 (2 uM) for 18 hours. Cells were 
then harvested, RNA prepared, and qPCR was performed (in duplicate) to monitor the expression of LXRα, LXRβ, ABCA1, 
or ABCG1. Expression values were averaged across donor cultures for each treatment and normalized to GAPDH. A and B: 
mean basal levels of LXRα (A) and LXRβ (B) in vehicle-treated cultures after 18 hours in culture for each cell type. C-G: 
expression in vehicle treated (open bars) or LXR-623 treated cultures (black bars) of LXRα (C), LXRβ (D), ABCA1 (E, F), and 
ABCG1 (G). All bars represent the mean of replicate cultures from all donors +/- SEM. All fold-changes indicated in the graphs 
were significant with p < 0.01 by Student's t test.
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ranged from 34,500–104,600 copies ABCG1/10^6 copies
GAPDH in the same subjects (data not shown).
Assessment of temporal profiles in each of the biomarker
transcripts in peripheral blood collected from a represent-
ative subject receiving LXR-623 (Figure 7, panels C and D)
revealed that peak transcriptional levels of ABCA1 and
ABCG1 were detected 4 hours post-dosing, after which the
levels of ABCA1 and ABCG1 decreased back to baseline
levels by twenty-four to forty-eight hours. Strong dose-
response and exposure-response relationships were
observed for ABCA1 and ABCG1 transcriptional biomark-
ers in subjects receiving ascending doses of LXR-623, and
these will be reported in a publication describing all of the
results of the single ascending dose study in detail (A. Katz
et al, submitted).
Discussion
The intent of this work was to identify easily accessible,
rapid, and robust indicators of LXR agonist exposure and
activity to aid in the clinical development of synthetic LXR
modulator compounds. An ideal surrogate tissue for such
ABCA1 and ABCG1 are upregulated in whole blood from human subjects following single-dose LXR-623 Figure 7
ABCA1 and ABCG1 are upregulated in whole blood from human subjects following single-dose LXR-623. Pan-
els A and B. Ten-fold dilutions (ranging from 10 to 100,000,000 copies) of ABCA1 and ABCG1 in vitro transcripts were reverse 
transcribed into cDNA and PCR amplified on an ABI 7900 real time PCR system. Representative amplification plots are shown 
for ABCA1 (A) and ABCG1 (B) with each dilution analyzed in triplicate (the 10 copy dilution standards gave CT's > 40 and are 
not shown on the graphs). For each analytical run, standard curves were generated from a dilution series of the calibrator tran-
scripts to allow accurate copy number estimation in clinical RNA samples. Panels C and D: whole blood was collected into 
PAXgene tubes two hours prior to dosing (-2 h) and at 2 h, 4 h, 12 h, 24 h and 48 h following a single dose of LXR-623. Time 
course results for a single representative subject receiving 75 mg/kg LXR-623 are depicted for both ABCA1 (C) and ABCG1 
(D) transcript levels. ABCA1 and ABCG1 transcript levels are expressed as actual copy numbers per million copies of GAPDH. 
Both transcripts exhibited similar fold elevations and followed identical time courses after LXR-623 exposure, with a maximal 
induction by 4 hours followed by a return to baseline levels after 24 hours.
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analyses is peripheral blood, but it was unclear whether
LXR agonist activity could be monitored in peripheral
blood. It was well known from the literature that activated
macrophages (usually tissue-associated and not freely cir-
culating in blood) respond to LXR agonists by increasing
the expression of certain LXR target genes such as the ABC-
cassette genes. Landis et al. [42] had previously reported
that treatment of purified human primary monocytes in
culture with a combination of oxidized LDL and 9-cis-
retinoic caused the induction of TNFα expression and
secretion, suggesting that LXRs may be expressed and
functional in peripheral blood cells. But subsequent
experiments to show that the monocytes' response to LXR
agonist treatment was mediated by LXR binding to an LXR
response element (LXRE) in the promoter of the TNFα
gene were performed in cells transfected with an expres-
sion vector containing LXRα [42], so proof that circulating
monocytes expressed functional LXRs was not conclu-
sively established. There have been some reports of LXR
expression and response to agonists in T-cells [43,44].
More recently, Siest et al [45] showed weak and variable
expression of LXRα and LXRβ mRNA in PBMC from nor-
mal human donors using custom microarrays. However,
this technique is relatively insensitive compared to qPCR,
and no data were provided on the functionality of LXRs in
PBMC. Therefore, we sought to determine whether tran-
scriptional biomarkers of LXR activity could be monitored
in peripheral blood.
Data presented here show that human peripheral blood
mononuclear cells express LXRα and LXRβ. Surprisingly,
functional LXR expression was found in T- and B-cells as
well as in monocytes ex vivo. Evaluation of the transcrip-
tional response of peripheral blood to synthetic LXR ago-
nists in vivo was first performed in rats and mice, where
expression of LXR target genes ABCA1 and ABCG1 was
found to be significantly increased by different LXR ago-
nist compounds, and as early as one hour following a sin-
gle oral dose of LXR-623. These observations were then
confirmed with experiments in higher species, in which
monkeys given daily doses of LXR agonist compound
showed robust and persistent expression changes in
ABCA1 and ABCG1 in peripheral blood RNA after 7 days
of dosing. These results were then extended to humans
using blood cells from healthy subjects treated ex vivo with
LXR-623. In both rats and humans given a single dose of
LXR-623, the induction of ABCA1 and ABCG1 expression
in peripheral blood cells tracked closely with plasma drug
levels. Intriguingly, the elevation of ABCA1 and ABCG1
mRNA was not sustained beyond the peak of plasma LXR-
623 concentration, suggesting a short in vivo t1/2 for these
two mRNAs and the dependence of mRNA levels prima-
rily upon transcription rate. This attribute is advantageous
for pharmacodynamic biomarkers.
We applied global transcriptional profiling to human
PBMC's treated with LXR-623 in culture to evaluate the
repertoire of gene expression in peripheral blood and to
determine whether the spectrum of transcriptional
changes appeared to have biological relevance. It was
found that many LXR target genes known to be regulated
in macrophage, liver, or duodenum were also regulated in
peripheral blood cells, and these genes were known to be
involved in reverse cholesterol transport and lipid metab-
olism. This observation, combined with an apparent cor-
relation between blood and spleen response to LXR
agonists in the rat, suggests that the LXR response that can
be monitored in peripheral blood may have clinical sig-
nificance and might ultimately provide surrogate tran-
scriptional markers of biological efficacy.
ABCA1 and ABCG1 were evaluated as pharmacodynamic
markers of LXR-623 exposure in a single ascending dose
study of LXR-623 in healthy human volunteers. In human
whole blood RNA, ABCA1 and ABCG1 responded with
similar temporal profiles following LXR-623 exposure in
a representative human subject, indicating that the com-
pound was appropriately engaging its target in vivo and
eliciting the expected biological response. Future studies
will attempt to correlate peripheral blood response to LXR
agonist compound with ultimate biological efficacy end-
points.
Conclusion
Peripheral blood cells show promise as a surrogate tissue
for monitoring the activity of LXR modulator compounds
in target organs. Several candidate biomarkers of LXR ago-
nist exposure and activity have been identified in periph-
eral blood, and two of these (ABCA1 and ABCG1) have
been demonstrated to change substantially (up to 200
fold change) and rapidly (≤ 4 hours) upon compound
treatment. These transcriptional markers have been
shown to be upregulated in peripheral blood cells from
rodents, primates, and humans, and the magnitude of
transcriptional induction of these biomarkers in periph-
eral blood cells closely corresponds to LXR agonist com-
pound concentration in serum. These LXR biomarkers
have already proven to be useful for the evaluation of a
novel synthetic LXR agonist in a human clinical study.
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